|United States Of America||Issued Patent||10,392,607||08/27/2019||2015-054|
|United States Of America||Published Application||20190345466||11/14/2019||2015-054|
|European Patent Office||Published Application||WO 2016/196655||12/08/2016||2015-054|
|Patent Cooperation Treaty||Published Application||WO2016196655||12/08/2016||2015-054|
RNA-programmed Cas9 has proven to be a versatile tool for genome engineering in multiple cell types and organisms. Guided by a dual-RNA complex or a chimeric single-guide RNA, Cas9 (or variants of Cas9) can generate site-specific double-stranded DNA breaks (DSBs) or single-stranded breaks (SSBs) within target nucleic acids. Target nucleic acids can include double-stranded DNA (dsDNA) and single-stranded DNA (ssDNA) as well as RNA. When cleavage of a target nucleic acid occurs within a cell, the break in the target nucleic acid can be repaired by non-homologous end joining or homology directed repair. UC Berkeley researchers have created new Cas9 protein variants, nucleic acids encoding the variant Cas9 proteins, and host cells comprising the nucleic acids.